KR102050339B1 - 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법 - Google Patents

빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법 Download PDF

Info

Publication number
KR102050339B1
KR102050339B1 KR1020137027053A KR20137027053A KR102050339B1 KR 102050339 B1 KR102050339 B1 KR 102050339B1 KR 1020137027053 A KR1020137027053 A KR 1020137027053A KR 20137027053 A KR20137027053 A KR 20137027053A KR 102050339 B1 KR102050339 B1 KR 102050339B1
Authority
KR
South Korea
Prior art keywords
interferon
dose
week
titration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137027053A
Other languages
English (en)
Korean (ko)
Other versions
KR20140038383A (ko
Inventor
아론 데이킨
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20140038383A publication Critical patent/KR20140038383A/ko
Application granted granted Critical
Publication of KR102050339B1 publication Critical patent/KR102050339B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
KR1020137027053A 2011-03-15 2012-03-15 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법 Active KR102050339B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US61/452,807 2011-03-15
US201161476930P 2011-04-19 2011-04-19
US61/476,930 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
KR20140038383A KR20140038383A (ko) 2014-03-28
KR102050339B1 true KR102050339B1 (ko) 2019-11-29

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027053A Active KR102050339B1 (ko) 2011-03-15 2012-03-15 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법

Country Status (25)

Country Link
US (6) US9198955B2 (cg-RX-API-DMAC7.html)
EP (1) EP2686002B1 (cg-RX-API-DMAC7.html)
JP (2) JP6279905B2 (cg-RX-API-DMAC7.html)
KR (1) KR102050339B1 (cg-RX-API-DMAC7.html)
CN (1) CN103702680A (cg-RX-API-DMAC7.html)
AU (1) AU2012229104B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013023609A8 (cg-RX-API-DMAC7.html)
CA (1) CA2846786C (cg-RX-API-DMAC7.html)
CY (1) CY1120176T1 (cg-RX-API-DMAC7.html)
DK (1) DK2686002T3 (cg-RX-API-DMAC7.html)
EA (1) EA028448B1 (cg-RX-API-DMAC7.html)
ES (1) ES2666850T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036931T2 (cg-RX-API-DMAC7.html)
IL (1) IL228425A (cg-RX-API-DMAC7.html)
LT (1) LT2686002T (cg-RX-API-DMAC7.html)
MX (1) MX359947B (cg-RX-API-DMAC7.html)
PL (1) PL2686002T3 (cg-RX-API-DMAC7.html)
PT (1) PT2686002T (cg-RX-API-DMAC7.html)
RS (1) RS57175B1 (cg-RX-API-DMAC7.html)
SG (1) SG193446A1 (cg-RX-API-DMAC7.html)
SI (1) SI2686002T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800221T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012125809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306933B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp 2室型プレフィルドシリンジ
US8932265B2 (en) * 2003-01-30 2015-01-13 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov archive for NCT01119677(최종 update 공지일: 2010.05.07.)*
MEDICATION GUIDE, AVONEX®, Interferon beta-1a(2003.05.)*

Also Published As

Publication number Publication date
EP2686002B1 (en) 2018-01-24
ES2666850T3 (es) 2018-05-08
MX359947B (es) 2018-10-17
NZ712273A (en) 2016-09-30
HUE036931T2 (hu) 2018-08-28
KR20140038383A (ko) 2014-03-28
IL228425A0 (en) 2013-12-31
AU2012229104B2 (en) 2017-03-16
SG193446A1 (en) 2013-10-30
DK2686002T3 (en) 2018-04-30
EA201301024A1 (ru) 2014-03-31
BR112013023609A2 (pt) 2016-12-06
NZ616536A (en) 2015-10-30
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
SI2686002T1 (en) 2018-06-29
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
ZA201306933B (en) 2016-07-27
IL228425A (en) 2017-08-31
EP2686002A1 (en) 2014-01-22
PT2686002T (pt) 2018-04-23
US20120237479A1 (en) 2012-09-20
JP6522069B2 (ja) 2019-05-29
JP6279905B2 (ja) 2018-02-14
WO2012125809A1 (en) 2012-09-20
US20160101157A1 (en) 2016-04-14
CY1120176T1 (el) 2018-12-12
JP2014508174A (ja) 2014-04-03
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
LT2686002T (lt) 2018-05-10
MX2013010507A (es) 2014-04-30
HRP20180621T1 (hr) 2018-07-27
CA2846786C (en) 2022-05-17
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
US20250276042A1 (en) 2025-09-04
SMT201800221T1 (it) 2018-07-17
EA028448B1 (ru) 2017-11-30
PL2686002T3 (pl) 2018-10-31
JP2018030847A (ja) 2018-03-01
US20220280610A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
US20250276042A1 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
US6869600B1 (en) Combined treatment of multiple sclerosis
Goodkin Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis
HK1192473B (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1192473A (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ616536B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
CN101180044B (zh) 用于自身免疫损伤后中枢神经系统神经再生的egf/ghrp-6组合
NZ712273B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170309

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180418

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180719

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190328

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190826

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221025

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231023

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 6

End annual number: 6